Excessive production of superoxide (O 2 d À ) in the central nervous system has been widely implicated in the pathogenesis of cardiovascular diseases, including chronic heart failure and hypertension. In an attempt to overcome the failed therapeutic impact of currently available antioxidants in cardiovascular disease, we developed a nanomedicine-based delivery system for the O 2 d À -scavenging enzyme copper/ zinc superoxide dismutase (CuZnSOD), in which CuZnSOD protein is electrostatically bound to a poly-L-lysine (PLL 50 )-polyethylene glycol (PEG) block copolymer to form a CuZnSOD nanozyme. Various formulations of CuZnSOD nanozyme are covalently stabilized by either reducible or nonreducible crosslinked bonds between the PLL 50 -PEG polymers. Herein, we tested the hypothesis that PLL 50 -PEG CuZnSOD nanozyme delivers active CuZnSOD protein to neurons and decreases blood pressure in a mouse model of angiotensin II (AngII)-dependent hypertension. As determined by electron paramagnetic resonance spectroscopy, nanozymes retain full SOD enzymatic activity compared to native CuZnSOD protein. Nonreducible CuZnSOD nanozyme delivers active CuZnSOD protein to central neurons in culture (CATH.a neurons) without inducing significant neuronal toxicity. Furthermore, in vivo studies conducted in adult male C57BL/6 mice demonstrate that hypertension established by chronic subcutaneous infusion of AngII is significantly attenuated for up to 7 days after a single intracerebroventricular injection of nonreducible nanozyme. These data indicate the efficacy of nonreducible PLL 50 -PEG CuZnSOD nanozyme in counteracting excessive O 2 d À and decreasing blood pressure in AngII-dependent hypertensive mice after central administration. Additionally, this study supports the further development of PLL 50 -PEG CuZnSOD nanozyme as an antioxidant-based therapeutic option for hypertension.
Excessive generation of reactive oxygen species, such as superoxide (O 2 d À ), has been extensively implicated in several neurologically associated cardiovascular pathologies, including hypertension [1] [2] [3] [4] [5] . As a major risk factor for myocardial infarction, stroke, heart failure, peripheral arterial disease, and chronic kidney disease, the morbidity and mortality associated with hypertension is a worldwide epidemic that is persistently rising [6] . Although there are several standard therapies that effectively lower blood pressure in many patients, 34% of hypertensive patients in the United States who are under medical management (approximately 16 million people taking angiotensin-converting enzyme inhibitors, angiotensin receptor blockers (ARBs), diuretics, and β-blockers) have uncontrolled blood pressure despite taking currently available prescription medications [7] . Thus, there is a need to develop new pharmacotherapies that target novel molecular effectors (e.g., O 2 dÀ ) that have been implicated by numerous studies to be integral in the pathogenesis of hypertension.
Angiotensin II (AngII), the primary effector peptide of the renin-angiotensin system, increases intracellular O 2 d À levels by activating the angiotensin type 1 receptor on central neurons [3, 8] . Our lab and others have previously shown that the AngII-induced increase in O 2 d À contributes to the activation of neurons by modulating potassium (K þ ) and calcium (Ca 2 þ ) channel activity [5, 9, 10] . Furthermore, AngII-induced activation of neurons in blood-brain barrier (BBB)-deficient brain regions has been shown to increase sympathoexcitation, which contributes to hypertensive symptoms such as increased vasoconstriction, enhanced sodium and water reabsorption in the kidney, increased heart rate, and activation of T lymphocytes and inflammatory cytokines [11] [12] [13] [14] [15] [16] [17] .
One specific BBB-deficient region of particular importance in cardiovascular regulation is the subfornical organ (SFO). The SFO lies at the roof of the third ventricle in the brain and is sensitive to circulating peptides and hormones and to experimental treatments directly injected into the intracerebroventricular (ICV) system. Previous studies have demonstrated the successful scavenging of AngII-induced O 2 d À with adenoviral-mediated overexpression of copper-zinc superoxide dismutase (CuZnSOD) in the SFO and other cardiovascular control brain regions, which in turn attenuates sympathetic drive and blood pressure in numerous hypertensive animal models [18] [19] [20] [21] [22] [23] [24] [25] . Although these studies convincingly demonstrate the beneficial anti-hypertensive effect of overexpressing CuZnSOD protein in the brain, clinical use of viral vectors in patients is limited by potential toxicity, overwhelming sequestration in the liver and aberrant inflammation [26] [27] [28] .
In an attempt to overcome the failed therapeutic potential of viral-mediated gene transfer of CuZnSOD and antioxidant drug delivery, our group has developed chemically distinct nanoformulated complexes with CuZnSOD protein (nanozymes). We previously reported that intracarotid injection of nanozyme complexes composed of polyethyleneimine (PEI)-polyethylene glycol (PEG) polymers, PEI-PEG, electrostatically bound to CuZn-SOD protein inhibits the central AngII-induced pressor response for 3 days [23] . In an attempt to expand the therapeutic window of CuZnSOD nanozymes beyond 3 days, we generated a novel nanozyme formulation consisting of CuZnSOD protein complexed with cationic block copolymers, poly-L-lysine (PLL 50 )-PEG [29] . We exploited the advantageous chemical properties of PLL 50 -PEG block copolymers and stabilized the complex by introducing reducible (disulfide) or nonreducible (amide) covalent bonds between the PLL 50 polymers using amine-reactive crosslinkers. Crosslinked nanozymes have been shown to significantly enhance the delivery of nanoformulated complexes in vitro and in vivo [29] [30] [31] .
Herein, we tested the hypothesis that crosslinked PLL 50 -PEG CuZnSOD nanozyme delivers functional CuZnSOD protein to neurons and attenuates blood pressure in chronically infused AngIIdependent hypertensive mice. We present data indicating that nonreducible crosslinked CuZnSOD nanozyme (cl-nanozyme) delivers active CuZnSOD protein to central neurons in culture without inducing significant toxicity and is capable of attenuating elevated blood pressure in AngII-dependent hypertensive mice after ICV administration.
Materials and methods

Preparation of PLL 50 -PEG CuZnSOD nanozyme
Synthesis, purification, and physicochemical characterization of PLL 50 -PEG CuZnSOD nanozymes were performed as previously described [29] . Briefly, native bovine CuZnSOD protein (SigmaAldrich, St. Louis, MO, USA) was mixed with PLL 50 -PEG cationic block copolymer (Alamanda Polymers, Huntsville, AL, USA). To covalently stabilize the CuZnSOD nanozymes ( Fig. 1) , reducible crosslinks were introduced using the commercially available chemical crosslinker 3,3 0 -dithiobis(sulfosuccinimidylproprionate) (DTSSP; Thermo Fisher Scientific, Rockford, IL, USA), whereas nonreducible crosslinks were introduced using bis(sulfosuccinimidyl)suberate (BS 3 ; Thermo Fisher Scientific). The molar ratios of DTSSP/PLL 50 and BS 3 /PLL 50 were 0.5 and 1.0, respectively. 
Electron paramagnetic resonance (EPR) spectroscopy
CATH.a neuronal cell culture
Mouse catecholaminergic CATH.a neurons were used, as they have previously been identified as a reliable neuronal cell culture model for investigating AngII intraneuronal signaling [32] [33] [34] . CATH.a neurons (ATCC, Stock CRL-11179) were cultured in RPMI 1640 medium, supplemented with 8% normal horse serum, 4% fetal bovine serum, and 1% penicillin-streptomycin and maintained in a humidified incubator at 37 1C with 5% CO 2 . Before experimentation, CATH.a neurons were differentiated for 6-8 days by adding N 6 ,2 0 -O-dibutyryladenosine 3 0 ,5 0 -cyclic monophosphate sodium salt (1 mM; Sigma) to the culture medium every other day, as we previously described [5] .
In vitro cytotoxicity assay CATH.a neuronal toxicity was assessed using the Cell Counting Kit-8 (CCK-8; Dojindo Molecular Technologies, Inc.) according to the manufacturer's directions. Briefly, CATH.a neurons were incubated with CCK-8 solution (1:10 in serum-free medium) for 1 h before experimental treatment to obtain a baseline measurement of viable cells in culture. The number of live cells was indicated by the level of colored formazan product, as determined by measuring absorbance at 450 nm. After baseline assessment, the same CATH.a neuronal cultures were incubated with the following treatment groups (each containing 400 U/ml CuZnSOD protein) for 1 and 3 h to assess neuronal viability: native CuZnSOD protein, noncrosslinked nanozyme, reducible cl-nanozyme, nonreducible cl-nanozyme, or the equivalent amount of PLL 50 -PEG polymer alone. Twenty-four hours after removal of treatment, the percent cell viability was calculated by normalizing post-treatment formazan absorbance values to pre-treatment (i.e., baseline) absorbance values. The viability of vehicle-treated CATH.a neurons was considered 100% survival.
Confocal microscopy and Western blot analysis
Neuronal uptake of CuZnSOD nanozyme was measured by labeling reducible cl-nanozyme and nonreducible cl-nanozyme with fluorescent rhodamine B isothiocyanate, as we have previously described [23] . Free rhodamine dye was removed from the labeled nanozyme sample by desalting the solution through an Illustra NAP-10 column (GE Healthcare). CATH.a neurons were treated for 1 or 3 h with the rhodamine-labeled formulations, and fluorescence images were captured with a Zeiss LSM 710 Meta confocal microscope.
To confirm neuronal delivery of nanozyme, we also performed Western blot analysis on cell lysates from differentiated CATH.a neurons exposed to the following treatment groups for 3 h: vehicle, 400 U/ml native CuZnSOD protein, 400 U/ml noncrosslinked nanozyme, 400 U/ml reducible cl-nanozyme, or 400 U/ml nonreducible cl-nanozyme. After treatment removal, the neurons were rinsed with 1 ml phosphate-buffered saline (PBS) and then incubated with 1 ml trypsin at 37 1C and 5% CO 2 for 5 min to assist with removal of extracellular-bound proteins and nanozymes. CATH.a neurons were subsequently scraped on ice and centrifuged at 6000g (4 1C, 6 min). The pellet was rinsed with 100 ml PBS to remove excess trypsin and centrifuged again at 6000g (4 1C, 6 min). Proteins were extracted using a lysis buffer (Complete Lysis-M; Roche Applied Science) and 25 Â protease inhibitor cocktail (P8340, Sigma-Aldrich) and incubating the samples on ice for 15 min. Samples were subsequently sonicated and then centrifuged at 21,000g (4 1C, 10 min). After protein concentration was determined, the samples were mixed with the 15 ml of 2 Â loading buffer and heated at 97 1C for 15 min. Protein (30 μg) was separated by electrophoresis on a 12% sodium dodecyl sulfatepolyacrylamide gel and transferred to a nitrocellulose membrane. Membranes were probed with rabbit primary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) against CuZnSOD (1:500) and actin (1:1000).
SOD activity assay
For determination of SOD activity levels, the same cell lysates as used for Western blot analysis were subjected to a total SOD Activity Kit-WST assay (Dojindo Molecular Technologies, Inc.) according to the manufacturer's directions.
AngII-infused mouse model of hypertension
Adult male C57Bl/6 mice ages 8-9 weeks (20-27 g; Harlan Laboratories, Indianapolis, IN, USA) were housed in an animal facility with a 12 h light-dark cycle and fed standard chow and water ad libitum. The following physiological parameters were measured daily in conscious mice using a radiotelemetry pressure transmitter device (Model TA11PA-C10, PhysioTel; Data Sciences International): mean arterial pressure (MAP), heart rate, systolic blood pressure (SBP), and diastolic blood pressure (DBP). Mice were anesthetized with isoflurane inhalation (0.5-2.0%) for subcutaneous implantation of the radiotelemetry device into the abdominal flank with the catheter inserted into the left carotid artery. Mice were also implanted with ICV cannulas under isoflurane anesthesia ( À 0.3 mm dorsal, þ1.0 mm lateral to the bregma, and À3.0 mm below the cerebral surface). Animals received topical bupivacaine on the procedure sites before the incision was closed with suture. After baseline blood pressure recordings for at least 3 days post-surgery, the mice were subcutaneously implanted under isoflurane anesthesia with osmotic minipumps (Model 1002, Alzet; Durect Corp.) set to infuse AngII (400 ng/kg/min, Sigma-Aldrich) over the period of several weeks. At day 9 of AngII infusion, when the mice were clearly hypertensive, a single bolus ICV injection of one of the following treatments was performed in conscious unrestrained mice: saline, PLL 50 -PEG shell, reducible cl-nanozyme, or nonreducible cl-nanozyme (130-150 U CuZnSOD activity). The mice were euthanized with an overdose of pentobarbital (150 mg/kg) administered by intraperitoneal injection. All procedures were performed in accordance with institutional guidelines for animal research reviewed and approved by the University of Nebraska Medical Center Institutional Animal Care and Use Committee.
Statistical analysis
All data are expressed as the mean 7 SEM. For the EPR experiments, cytotoxicity, and Western blot analysis, one-way ANOVA with Dunnett's post hoc test was performed. For the SOD activity assay, Student's t test with Welch's correction was performed. For the in vivo experiments, we performed repeated-measures twoway ANOVA with Dunnett's post hoc test using time as a withinsubject factor and treatment as a between-subject factor. A P value less than 0.05 was considered statistically significant. Statistical analyses were performed using Prism (GraphPad Software, Inc.) or Statistical Package for Social Sciences software (SPSS, Inc.).
Results
CuZnSOD nanozymes scavenge superoxide
To examine the activity of CuZnSOD nanozymes, we tested their ability to scavenge O 2 d À in a cell-free system using EPR spectroscopy. The reducible cl-nanozyme and nonreducible clnanozyme were as effective as native CuZnSOD protein in decreasing the EPR spectra ( Fig. 2A ). Summary data (Fig. 2B) clearly reveal a significant decrease in EPR spectrum amplitude in all samples containing CuZnSOD compared to vehicle. These data clearly validate the O 2 d À -scavenging capacity of our PLL 50 -PEG CuZnSOD nanozyme formulations and confirm that the nanozyme structure does not preclude access to the substrate nor does the protein need to be released for it to catalyze O 2 d À dismutation, as previously reported [35, 36] .
Nonreducible crosslinked nanozyme is the least toxic formulation in vitro
We next determined the potential neuronal toxicity induced by nanozyme treatment in vitro. CATH.a neurons were treated for 1 or 3 h with vehicle, native CuZnSOD protein, PLL 50 -PEG shell alone, noncrosslinked nanozyme, reducible cl-nanozyme, or nonreducible cl-nanozyme, and 24 h later cell survival was determined. Summary data (Fig. 3 ) reveal no significant difference in survival between neurons treated with native CuZnSOD protein and those treated with vehicle. However, PLL 50 -PEG shell alone, noncrosslinked nanozyme, and reducible cl-nanozyme did induce significant toxicity. In contrast, the nonreducible cl-nanozyme did not induce neuronal cell death after 1 h treatment. However, there was a modest decline in cell survival after 3 h treatment with nonreducible cl-nanozyme. These data identify nonreducible clCuZnSOD nanozyme as the safest formulation tested in cultured neurons.
Crosslinked nanozymes enhance neuronal uptake of CuZnSOD protein
To evaluate the ability of cl-nanozymes to be taken up by neurons in culture, CATH.a neurons were exposed to fluorescent rhodamine-labeled CuZnSOD nanozymes for either 1 or 3 h. Representative confocal microscopy images (Fig. 4) of CATH.a neurons exposed to cl-nanozymes reveal uptake of either reducible cl-nanozyme or nonreducible cl-nanozyme as early as 1 h after exposure, with even greater uptake after 3 h, as indicated by increased red fluorescence.
Nonreducible crosslinked nanozyme delivers active CuZnSOD protein to neurons
To confirm uptake of nanozymes in vitro, Western blot analysis was performed on lysates from CATH.a neurons treated for 3 h with vehicle, native CuZnSOD protein, noncrosslinked nanozyme, reducible cl-nanozyme, or nonreducible cl-nanozyme. The representative Western blot and summary data (Fig. 5A) show a significant increase in CuZnSOD protein levels in neurons treated with nonreducible cl-nanozyme. It should be noted that the bovine CuZnSOD protein, which is used in our nanozymes, migrates slower in gel electrophoresis. Next, we examined the activity of nanozyme-delivered CuZnSOD protein. SOD activity in CATH.a neurons treated with native CuZnSOD protein, noncrosslinked nanozyme, and reducible cl-nanozyme was slightly elevated compared to vehicle-treated neurons, although these differences were not statistically significant (Fig. 5B) . However, SOD activity was significantly elevated in neurons treated with nonreducible cl-nanozyme. Collectively, the confocal microscopy images (Fig. 4) , Western blot analysis (Fig. 5A) , and SOD activity assay (Fig. 5B) clearly identify the nonreducible cl-nanozyme as the most effective formulation in delivering active CuZnSOD protein to neurons in culture.
ICV-administered nonreducible crosslinked CuZnSOD nanozyme significantly attenuates AngII-dependent hypertension
We next evaluated the anti-hypertensive therapeutic potential of our cl-nanozymes in an AngII-infused hypertensive mouse model. MAP was recorded from mice subcutaneously infused with AngII (400 ng/kg/min) before and after a single ICV injection of saline, PLL 50 -PEG shell alone, reducible cl-nanozyme, or nonreducible cl-nanozyme. An immediate (i.e., within 24 h) increase in blood pressure after implantation of AngII-filled osmotic minipumps was observed in all groups, with an average increase of 24 mm Hg on day 1 of AngII infusion (Fig. 6A ). There were no significant differences in the degree of elevation in MAP between the various groups of mice at day 1 of AngII infusion (P 40.05). Mice were ICV injected with the treatments listed above at day 9 of AngII infusion, as this was the time point at which the blood pressures stabilized in the hypertensive range (average MAP 131 mm Hg; average change from baseline (day 0) MAP 42 mm Hg; Po0.05 versus baseline MAP in each respective group). Importantly, the hypertensive MAPs at day 9 were similar between all groups with no significant differences observed (P 40.05): saline 128 73 mm Hg, PLL 50 -PEG shell 1237 3 mm Hg, reducible cl-nanozyme 13875 mm Hg, nonreducible clnanozyme 1337 5 mm Hg.
After a single ICV injection of saline, PLL 50 -PEG shell, or reducible cl-nanozyme at day 9 of AngII infusion, mice continued to remain hypertensive for the duration of AngII infusion (Fig. 6A) . In contrast, ICV injection of nonreducible cl-nanozyme significantly decreased MAP and DBP within 24 h and for up to 7 days (Figs. 6A and D). There was also a decrease, although not statistically significant (P¼0.085), in SBP in mice ICV injected with nonreducible cl-nanozyme (Fig. 6C) . ICV injection of saline, PLL 50 -PEG shell, reducible cl-nanozyme, or nonreducible cl-nanozyme did not alter heart rate (Fig. 6B) . It should be noted that MAP, SBP, and DBP in all groups returned to near baseline (ca. day 20-21 of AngII infusion) after the AngII-filled osmotic minipumps emptied. These in vivo data indicate that the nonreducible cl-nanozyme attenuates AngIIdependent hypertension after ICV administration.
Discussion
This study demonstrates the utility of PLL 50 -PEG nanoformulated CuZnSOD protein as a potentially viable pharmacotherapy for AngII-dependent neurogenic hypertension. The data presented in this study reveal that CuZnSOD cl-nanozymes retain enzymatic activity and are able to effectively scavenge O 2 d À . Furthermore, the nonreducible cl-nanozyme delivers active CuZnSOD protein to central neurons in culture more efficiently than native CuZnSOD protein, noncrosslinked nanozyme, or the reducible cl-nanozyme. Last, our in vivo experiments demonstrate the therapeutic potential of the nonreducible cl-nanozyme formulation and its ability to significantly attenuate hypertensive blood pressure for up to 7 days after a single ICV injection in AngII-hypertensive mice. Taken together, our data strongly support the further development of nonreducible cl-nanozymes for the improved treatment of hypertension in which there are excessive levels of O 2 d À in the central nervous system.
Previous studies by numerous groups have clearly demonstrated that increased scavenging of O 2 dÀ in the brain, via adenoviral-mediated overexpression of CuZnSOD or SOD mimetics, decreases blood pressure and attenuates sympathoexcitation in various animal models of hypertension [18] [19] [20] [21] [22] [23] [24] [25] . For example, adenovirusmediated overexpression of CuZnSOD in the SFO or rostral ventrolateral medulla (RVLM) of the brain decreases blood pressure in AngII-infused hypertensive mice and spontaneously hypertensive rats, respectively [18, 19] . In addition, CuZnSOD overexpression in the RVLM decreases blood pressure and reduces sympathetic vasomotor tone in the two-kidney-one-clip hypertensive rat model [37] . Central administration of tempol, an SOD mimetic, attenuates the increase in blood pressure and renal sympathetic nerve activity induced by ICV infusion of AngII [38] . Although these previous studies and others have convincingly demonstrated a beneficial anti-hypertensive effect of overexpressing O 2 d À scavengers in the brain, the use of viral vectors or SOD mimetics in clinical practice is limited by poor cellular uptake, rapid clearance, toxicity, end-organ sequestration, and/or inflammation [26] [27] [28] . Furthermore, it is essential to develop clinically acceptable therapeutic strategies with relevant routes of drug delivery (i.e., intravenous, intranasal, or sublingual administration). Thus, it becomes increasingly important to investigate new therapeutic strategies that may address these pharmacokinetic obstacles in drug delivery and development.
Collectively, the extensive evidence establishing the benefit of scavenging O 2 d À in the brain provides rationale for our experiments in which we investigate the efficacy of a therapeutically relevant antioxidant strategy for the improved treatment of hypertension. One promising drug delivery option includes implementation of nanotechnology. The utilization of nanoparticles has been shown to improve solubility and long-term stability of pharmacological agents through the prevention of premature clearance by the renal or reticuloendothelial systems [39] . As such, we believe there is great utility in developing nanoformulated CuZnSOD protein as an antioxidant therapeutic strategy for hypertension. We previously reported that a noncrosslinked formulation of CuZnSOD nanozyme, in which the block copolymer PEI-PEG is electrostatically bound to CuZnSOD protein, inhibits the acute central AngII-induced pressor response for 3 days [23] . These initial experiments prompted us to explore other chemically distinct nanoformulations, in which complexes are stabilized with reducible or nonreducible crosslinked bonds between the PLL 50 -PEG block copolymers, with the intention of expanding the therapeutic window. Using these crosslinked complexes and a more relevant model of hypertension (i.e., chronic subcutaneous infusion of AngII) in the current study, our data presented herein clearly demonstrate the O 2 d À -scavenging capacity of crosslinked nanozymes and identify the nonreducible cl-nanozyme as the ideal nanoformulation to safely deliver active CuZnSOD protein to neurons in culture. Furthermore, the nonreducible CuZnSOD clnanozyme significantly decreased MAP and DBP in AngII hypertensive mice after ICV administration. In addition, SBP was decreased, although not statistically significant (P¼0.085), in mice ICV injected with the nonreducible cl-nanozyme. Collectively, these data suggest that ICV-administered nonreducible cl-nanozyme decreases blood pressure in AngII-dependent hypertensive mice by influencing both preload and afterload and inhibiting sympathetic output. Future studies in which the nonreducible cl-nanozyme is peripherally administered (i.e., intravenously, intranasally, or sublingually) are needed to determine the direct effect, if any, of the nanozyme on cardiac function.
The integral involvement of O 2 d À in the pathogenesis of hypertension has been implicated and recapitulated in numerous animal models over the years. As O 2 d À is a downstream signaling molecule in the renin-angiotensin-aldosterone system (RAAS) pathway, there is also mounting evidence that excessive levels of it in hypertension are generated by immunological changes (i.e., activation of T cells and cytokines) [14, 15, [40] [41] [42] . As such, we posit our O 2 d À -scavenging CuZnSOD nanozymes may have an added benefit over traditionally prescribed pharmacotherapies for hypertension, which specifically target the RAAS pathway (e.g. ARBs and ACE inhibitors), as they will scavenge O 2 d À produced from multiple stimuli (i.e., AngII and cytokines). In fact, it has been reported that increased O 2 d À scavenging in hypertensive rats via peripheral administration of tempol prevents vascular dysfunction and improves renal blood perfusion to a greater extent than the ARB candesartan [43, 44] . To this extent, future studies will not only compare our peripherally administered CuZnSOD nanozymes with standard anti-hypertensive medications, but also examine the synergistic or additive therapeutic efficacy of CuZnSOD nanozyme given in combination with standard antihypertensive drugs.
Although the results from our current study are promising, there are several considerations that must be addressed in further developing this nanoformulated therapeutic strategy for human hypertensive patients resistant to currently available pharmacotherapy. Considering that previous studies have shown that increased O 2 d À scavenging in neurons inhibits the AngII-induced modulation of ion channel activity and increases neuronal firing [23, 45] , we speculate that neurons in cardiovascular control brain regions surrounding the ventricular system, such as the SFO, internalize the nonreducible cl-nanozyme after ICV injection. However, because our nanozymes are not designed to specifically target neurons, it is plausible that other cell types in the brain also internalize the complexes. It is certainly feasible to further develop nanoparticles to target cell-specific populations, as Muzykantov and colleagues have successfully performed with other CuZnSOD nanoformulations targeted to endothelial cells [46] [47] [48] [49] [50] . Nonetheless, supplementary studies are needed to determine the cellular distribution of nonreducible cl-nanozyme after in vivo administration.
In addition, the precise subcellular localization of the clnanozymes after neuronal uptake remains unclear. However, there seems to be a clear distinction in the cellular distribution of reducible cl-nanozyme versus nonreducible cl-nanozyme, as indicated by the representative confocal microscopy images (Fig. 4) . The reducible formulation shows punctate staining throughout the cell, whereas the nonreducible formulation shows both punctate staining in the cell and distribution along the plasma membrane. We believe this differential distribution is a reflection of the distinct chemical properties of the two crosslinked formulations. The reducible cl-nanozyme is composed of disulfide bonds, which may easily disassociate in the intracellular reducing environment, whereas the nonreducible cl-nanozyme is composed of more stable amide bonds and is thus more likely to remain intact in the intracellular environment. We posit that the nonreducible clnanozyme association with the plasma membrane may be of therapeutic benefit, as it could easily scavenge O 2 d À generated from membrane-bound NADPH oxidase, one of the primary sources of AngII-induced O 2 d À production in neurons [2] . This theory may indeed identify the mechanism whereby nonreducible cl-nanozyme achieves therapeutic efficacy after ICV injection in vivo (Fig. 6A) . However, additional studies are needed to address this hypothesis. An additional explanation as to why the reducible cl-nanozyme had no effect on the elevated MAP in the AngII-infused mice is that the disulfide bonds between the polymers are reduced upon injection into the brain, which allows for the polymer to dissociate from the protein, resulting in the release of CuZnSOD protein from the complex. It is well accepted that free CuZnSOD protein does not permeate cell membranes and thus the reducible cl-nanozyme may fail to deliver active CuZnSOD protein to neurons in vivo. These theories identify potential mechanisms whereby nonreducible cl-nanozyme, but not reducible cl-nanozyme, achieves therapeutic efficacy after ICV injection.
It is important to highlight that our cell culture experiments were performed using the catecholaminergic CATH.a neuronal cell line. Although these neurons have been widely identified in the literature as exhibiting AngII intraneuronal signaling mechanisms similar to those of primary neurons isolated from the hypothalamus and brain stem [33] , future experiments must include the utilization of primary neurons cultured from the brains of AngIIinfused hypertensive mice. Additionally, we must consider that the potential toxicity of the cl-nanozymes in vitro may not necessarily duplicate the noxious or immunogenic mechanisms that occur in a full-body in vivo animal model. With regard to our in vitro toxicity study (Fig. 3) , the PLL 50 -PEG shell causes a marked decrease in neuronal cell survival most likely because the highly positively charged PLL polymers damage the cells via interaction with the negatively charged cell membrane and other macromolecules. This toxicity induced by positively charged polymers is well documented [51, 52] . It should also be noted that we posit that the noncrosslinked CuZnSOD nanozyme is as toxic as the PLL 50 -PEG shell alone because the polymer shell dissociates from the enzyme (as it is not crosslinked), allowing for free positively charged PLL 50 -PEG to damage the cells. Furthermore, we speculate that upon entering the reducing intracellular environment, the reducible disulfide bonds between the PLL polymers of the reducible cl-nanozyme are cleaved and consequently release the positively charged and cytotoxic PLL 50 -PEG shell, resulting in mild, yet significant neuronal toxicity (Fig. 3) . These toxicity data may provide some explanation for the discrepancy between the CuZn-SOD protein and activity levels detected in the noncrosslinked nanozyme group (Fig. 5) . It should be noted that the SOD activity assay we used does not specifically measure CuZnSOD activity; rather, it measures total SOD activity (including manganese SOD and extracellular SOD). Cells treated with noncrosslinked nanozyme did not show an increase in CuZnSOD protein, but did show an increase, although not statistically significant compared to vehicle-treated cells, in SOD activity. We posit that the increase in SOD activity observed in the noncrosslinked nanozyme treated cells is due to increased activity of the other SOD isozymes. We believe the other SOD isozymes, particularly MnSOD, may become more active in these cells in an attempt to combat the toxicity induced by the noncrosslinked nanozyme formulation, as shown in Fig. 3 . However, additional experiments are needed to test this hypothesis. Collectively, these data further support the benefit, in terms of potential cellular toxicity, for chemically crosslinking the PLL 50 -PEG shell with nonreducible covalent bonds. Nonetheless, it will be imperative to investigate the potential cellular toxicity in multiple cell populations (e.g., endothelial cells, astroglia, microglia, oligodendrocytes, etc.) and following more clinically relevant routes of cl-nanozyme administration in vivo.
In conclusion, the experimental data presented in this paper provide sufficient evidence supporting the delivery of active CuZnSOD protein to neurons by nanomedicine-based technologies for the treatment of AngII-dependent hypertension. This distinct crosslinked nanoformulated drug delivery system provides an alternative strategy for targeting specific downstream signaling molecules in the RAAS pathway, namely O 2 d À , known to play a critical role in the pathogenesis of hypertension. The promising results from our in vitro experiments, coupled with the therapeutic efficacy as illustrated by the attenuated blood pressures in AngII-infused hypertensive mice after central administration with nonreducible cl-nanozyme, warrant further investigation to pursue these novel nanoformulations as a therapeutic option for the improved treatment of hypertension.
